Clinical trial Recruiting at 1 site Observational Ages 18 and up

Rapid blood test using GFAP to tell hemorrhagic vs ischemic stroke

Official title: Biomarkers Based EArly Diagnosis of STroke Subtype Cohort, Bio-EAST

Run by Shanghai East Hospital · NCT07003477 · Data updated 2026-11-12

This project will test whether a quick blood test for GFAP can tell if adults with suspected stroke have bleeding in the brain when they arrive within three hours of symptom onset.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment527 (estimated)
SponsorShanghai East Hospital
Academic / other
Locations1 site (Shanghai, Shanghai Municipality)
StatusRecruiting
StartedJune 12, 2025
Main results expectedAugust 30, 2028
Study endsNovember 30, 2028
Registry record updatedJanuary 21, 2026
Trial IDNCT07003477 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 or older who arrive with suspected stroke (FAST score ≥2 including limb weakness) within three hours of symptom onset are ideal candidates for this project.

Probably not a fit

Patients in coma, with severe comorbidities that limit daily living, recent head trauma, seizure-onset strokes, or very low blood glucose are excluded and may not benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational cohort will enroll adults with suspected stroke who present within three hours and collect peripheral blood to measure GFAP and other biomarkers. The project partners hospitals with industry to develop and validate a rapid diagnostic workflow aimed at pre-hospital and emergency use. Results will be compared to clinical imaging to determine how well the biomarker distinguishes intracerebral hemorrhage from ischemic stroke. The goal is to produce data that could support faster, guided treatment decisions in the ambulance or emergency department.

Why it matters

Potential benefit: If successful, the test could allow clinicians to identify intracerebral hemorrhage quickly and start appropriate treatments sooner, potentially improving outcomes.

How similar studies have gone: Prior clinical work has shown GFAP is highly specific for intracerebral hemorrhage and trials like INTERACT4 demonstrated benefit of very early blood-pressure lowering, but deploying GFAP as a rapid pre-hospital diagnostic tool is a newer application.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age ≥ 18 years old;
2. Suspected stroke at emergency department arrival (FAST score ≥ 2 points, must include limb weakness);
3. Time of stroke symptom onset/last known normal within 3 hours.

Exclusion Criteria:

1. Coma - no response to tactile or verbal stimuli;
2. Severe comorbidities (such as tumors, severe COPD, severe heart failure, requiring assistance with daily living \[unable to walk independently\]);
3. History of epilepsy or onset with seizure;
4. Recent history of head trauma (\< 7 days);
5. Blood glucose \< 2.8 mmol/L.

Where it's running

  • Shanghai East Hospital
    Shanghai, Shanghai Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.